Press "Enter" to skip to content

Norway biotech Ultimovacs plans IPO to develop cancer drug

Ultimovacs hopes to first get the go-ahead to expand a U.S. trial launched earlier this year to test whether its UV1 vaccine candidate can combat malignant melanoma in combination with Merck & Co’s top-selling cancer treatment Keytruda.

Original source: